Nitzan Rosenfeld
#176,629
Most Influential Person Now
Researcher
Nitzan Rosenfeld's AcademicInfluence.com Rankings
Nitzan Rosenfeldlaw Degrees
Law
#3162
World Rank
#3978
Historical Rank
Common Law
#198
World Rank
#215
Historical Rank
International Law
#1249
World Rank
#1497
Historical Rank
Nitzan Rosenfeldengineering Degrees
Engineering
#8368
World Rank
#9900
Historical Rank
Cybernetics
#182
World Rank
#190
Historical Rank
Biomedical Engineering
#851
World Rank
#864
Historical Rank
Download Badge
Law Engineering
Nitzan Rosenfeld's Degrees
- PhD Biomedical Engineering Tel Aviv University
- Masters Biomedical Engineering Tel Aviv University
- Bachelors Biomedical Engineering Tel Aviv University
Why Is Nitzan Rosenfeld Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nitzan Rosenfeld is a professor of Cancer Diagnostics at the University of Cambridge. He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and co-founder of Inivata, a clinical cancer genomics company.
Nitzan Rosenfeld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Analysis of circulating tumor DNA to monitor metastatic breast cancer. (2013) (1628)
- Liquid biopsies come of age: towards implementation of circulating tumour DNA (2017) (1532)
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (2013) (1472)
- Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. (2007) (1385)
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016) (1125)
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (2012) (1125)
- Gene Regulation at the Single-Cell Level (2005) (1119)
- Dynamics of the p53-Mdm2 feedback loop in individual cells (2004) (1010)
- MicroRNAs accurately identify cancer tissue origin (2008) (984)
- Negative autoregulation speeds the response times of transcription networks. (2002) (705)
- Oscillations and variability in the p53 system (2006) (641)
- Variability and memory of protein levels in human cells (2006) (575)
- Enhanced detection of circulating tumor DNA by fragment size analysis (2018) (525)
- Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension (2013) (429)
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer (2015) (397)
- Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. (2013) (381)
- Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. (2009) (379)
- Measuring single-cell gene expression dynamics in bacteria using fluorescence time-lapse microscopy (2011) (334)
- Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer (2015) (322)
- Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis (2015) (313)
- Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis (2014) (306)
- Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma (2016) (254)
- MiR‐92b and miR‐9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors (2008) (205)
- Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study (2016) (183)
- Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA (2017) (152)
- Response delays and the structure of transcription networks. (2003) (144)
- Circulating tumor-derived DNA is shorter than somatic DNA in plasma (2015) (126)
- Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin (2010) (119)
- Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma (2014) (115)
- Accurate molecular classification of renal tumors using microRNA expression. (2010) (113)
- A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. (2010) (110)
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer (2018) (102)
- Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients (2018) (100)
- MicroRNAs as a potential prognostic factor in gastric cancer. (2010) (99)
- Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA (2018) (94)
- A fluctuation method to quantify in vivo fluorescence data. (2006) (89)
- CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response (2020) (88)
- Circulating tumor DNA to monitor metastatic breast cancer. (2013) (86)
- ctDNA monitoring using patient-specific sequencing and integration of variant reads (2020) (80)
- Accurate prediction of gene feedback circuit behavior from component properties (2007) (80)
- Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling (2018) (79)
- Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
- Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer (2017) (70)
- Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients (2018) (69)
- Are liquid biopsies a surrogate for tissue EGFR testing? (2018) (58)
- Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. (2018) (57)
- Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors (2020) (55)
- Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer (2018) (51)
- Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes (2016) (50)
- Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. (2010) (49)
- A phylogenetic latent feature model for clonal deconvolution (2016) (39)
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer (2022) (37)
- Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients (2021) (36)
- EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter (2013) (35)
- Exploratory Analysis of TP 53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma : A Retrospective Study (2016) (34)
- Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer (2019) (32)
- Selecting short DNA fragments in plasma improves detection of circulating tumour DNA (2017) (28)
- Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer (2019) (23)
- The future of early cancer detection (2022) (23)
- Abstract 3639: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay (2016) (20)
- Detection of ctDNA from Dried Blood Spots after DNA Size Selection. (2020) (19)
- Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA (2021) (13)
- Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma (2020) (12)
- Refined characterization of circulating tumor DNA through biological feature integration (2021) (11)
- High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads (2019) (10)
- CVE: an R package for interactive variant prioritisation in precision oncology (2017) (8)
- Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations (2020) (7)
- Detection of ctDNA from dried blood spots after DNA size selection (2019) (6)
- Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (2022) (5)
- Liquid biopsies for residual disease and recurrence. (2021) (5)
- MA 11.02 Circulating Tumor DNA in Early Stage NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update (2017) (4)
- Differential diagnosis of mesothelioma using a microRNA assay (2008) (4)
- Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC. (2021) (4)
- Abstract 735: Sensitive detection of ctDNA in early stage non-small cell lung cancer patients with a personalized sequencing assay (2020) (4)
- Abstract 4581: Feasibility of an amplicon-based liquid biopsy forALKandROS1fusions in advanced non-small cell lung cancer (NSCLC) patients (2018) (3)
- Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform. (2015) (3)
- Abstract 3097: Analytical development of the RaDaRTMassay, a highly sensitive and specific assay for the monitoring of minimal residual disease (2020) (3)
- Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models (2022) (3)
- Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic reconstruction (2015) (3)
- Integrated clonal analysis reveals circulating tumor DNA in urine and plasma of glioma patients (2019) (3)
- Detection of residual disease and recurrence in early-stage non-small cell lung cancer (NSCLC) patients using sensitive personalized ctDNA sequencing assays. (2020) (3)
- ctDNA detection by personalised assays in early-stage NSCLC (2021) (2)
- P3.02b-102 Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients: Topic: EGFR RES (2017) (2)
- Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples (2016) (2)
- High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial (2023) (2)
- Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer. (2016) (2)
- Targeted Deep Sequencing of Plasma DNA Noninvasive Identification and Monitoring of Cancer Mutations by (2012) (2)
- Comprehensive characterisation of cell-free tumour DNA in plasma and urine of patients with renal tumours (2019) (2)
- Identification of tumor tissue origin by a microRNA-based molecular assay. (2009) (2)
- Individualised monitoring of patients with metastatic melanoma using plasma DNA (2017) (1)
- Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells (2012) (1)
- Abstract B7: Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform (2015) (1)
- Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA (ctDNA) in metastatic breast cancer. (2017) (1)
- Abstract 736: ctDNA detection in early stage non-small cell lung cancer (2020) (1)
- Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene (2020) (1)
- Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors (2019) (1)
- Abstract 2743: Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer (2017) (1)
- Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients. (2016) (1)
- Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients (2021) (1)
- Reply to G. Rossi et al (2009) (1)
- Abstract SY11-03: Circulating tumor DNA as a non-invasive diagnostic and research tool. (2013) (0)
- 935 The Timing of Oncogenic Events in the Evolution of the Oesophageal Adenocarcinoma Genome and Implications for Clinical Diagnostics (2014) (0)
- Abstract 447: Sensitive detection of ctDNA in low burden and ‘challenging’ cancers (2019) (0)
- PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer (2018) (0)
- Multimodality Approaches to Screening for Lung Cancer. (2019) (0)
- Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer (2017) (0)
- OC-066 The Cancer Research UK (Cruk) Funded ICGC Oesophageal Adenocarcinoma Project: MRC Research Centre and Cruk Cambridge Research Institute (2013) (0)
- Abstract 1273: Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay (2022) (0)
- 144P A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer (2021) (0)
- The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer (2016) (0)
- Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (2023) (0)
- Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients (2016) (0)
- P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients (2018) (0)
- Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL (2017) (0)
- 1770P Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO) (2022) (0)
- Abstract 2412: Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform (2015) (0)
- A pilot study of individualised monitoring of patients with metastatic melanoma using plasma and urine DNA. (2017) (0)
- P2.03b-093 Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories: Topic: Biomarkers (2017) (0)
- MicroRNA expression profile identifies origin of tumors in the liver (2008) (0)
- Clonal expansion index stratifies patients into prognostic subgroups. (2015) (0)
- CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes. (2016) (0)
- Hamlet.rt Trans: a prospective single-centre translational sub-study evaluation of liquid biomarkers of radiation response (2023) (0)
- Scientific Programme Committee (2000) (0)
- Monitoring metastatic melanoma treatment resistance using circulating tumour DNA (2016) (0)
- Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell Lung Cancer Patients Receiving EGFR-Targeted Therapies (2015) (0)
- MicroRNA-based assay for differential diagnosis of squamous from non-squamous non-small cell lung carcinoma. (2009) (0)
- A large-scale retrospective study in metastatic breast cancer patients using circulating tumor DNA and machine learning to predict treatment outcome and progression-free survival (2023) (0)
- CVE: an R package for interactive variant prioritisation in precision oncology (2017) (0)
- 58: Proffered Paper: Noninvasive monitoring of tumour mutations and dynamics in circulating DNA of non-small cell lung cancer patients treated with EGFR inhibitors (2014) (0)
- PD56-03 DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA (2018) (0)
- MA16.02 Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC (2018) (0)
- Forshew 1..12 (2019) (0)
- Abstract #5394: MicroRNA-based assay for differential diagnosis of squamous from non-squamous non small cell lung carcinoma (2009) (0)
- Noninvasive monitoring of cancer dynamics using circulating tumour DNA (2013) (0)
- A microRNA-based diagnostic assay distinguishes squamous from non-squamous non small-cell lung carcinoma (2008) (0)
- Regulation and Fluctuation of a Genetic Element at the Single-Cell Level (2004) (0)
- Abstract P2-01-07: Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based sequencing approach (2022) (0)
- [Acute disseminated lupus erythematosus. Responsibility of Corenitec: apropos of a case]. (1999) (0)
- MicroRNA signature identifies tissue origin of primary and metastatic tumors (2008) (0)
- PTU-153 The Timing Of Oncogenic Events In The Evolution Of The Oesophageal Adenocarcinoma Genome And Implications For Clinical Diagnostics (2014) (0)
- Abstract 1377: Improved ctDNA detection in early stage non-small-cell lung cancer (2019) (0)
- MicroRNAs as specific biomarkers for distinguishing between primary and metastatic brain tumors (2008) (0)
- Integrative analysis reveals novel subtypes of medulloblastoma subgroups (2017) (0)
- EP-1368 Circulating cell free DNA during chemoradiotherapy in non-small cell lung cancer patients (2019) (0)
- Abstract IA16: Enhancing detection of ctDNA in patients with early-stage or residual disease (2020) (0)
- 876 Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells (2012) (0)
- LBA-14 COMPREHENSIVE CHARACTERISATION OF CIRCULATING TUMOUR DNA IN PLASMA AND URINE OF PATIENTS WITH RENAL TUMOURS: RESULTS OF THE DIAMOND AND MONREC STUDIES (2019) (0)
- Abstract 939: Analytical validation of InVisionFirst™, a liquid biopsy assay for high-sensitivity broad molecular profiling of circulating tumor DNA using plasma samples of cancer patients (2018) (0)
- Proffered Paper: Enhancing sensitivity for analysis of circulating tumour DNA (2016) (0)
This paper list is powered by the following services:
Other Resources About Nitzan Rosenfeld
What Schools Are Affiliated With Nitzan Rosenfeld?
Nitzan Rosenfeld is affiliated with the following schools:
